Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.25259/IJDVL_687_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brazilian experience with oral atenolol in the treatment of infantile hemangiomas.
An Bras Dermatol
November 2024
Department of Dermatology, Hospital das Clínicas, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil.
Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study.
Dermatology
December 2024
Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Introduction: Propranolol is the first-line treatment for complicated infantile hemangioma (IH). Rebound growth following propranolol discontinuation is reported in 6-25% of patients. Atenolol is considered an effective alternative to propranolol.
View Article and Find Full Text PDFEfficacy and safety of atenolol versus propranolol for treatment of infantile haemangioma: A narrative review.
Clin Exp Dermatol
October 2024
Department of Paediatric Dermatology, Sydney Children's Hospital Randwick.
Article Synopsis
- Infantile haemangiomas (IH) are the most common benign vascular tumors in children and often require treatment for cases that cause disfigurement or functional impairment.
- Propranolol has been the first-line treatment since 2008, but it can lead to side effects like hypoglycemia and sleep disturbances.
- Atenolol, a different beta blocker, has shown similar effectiveness with fewer adverse effects, suggesting it might be a better alternative, although more research is needed on dosing and managing rebound growth.
Infantile hemangiomas: a dermatologist's perspective.
Eur J Pediatr
October 2024
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Infantile hemangioma (IH), the most common vascular tumor in pediatrics, is thought to arise from aberrant stem cell responses to stimuli such as hypoxia. This review explores the diverse manifestations, complications, and management strategies for IH, emphasizing the importance of a multidisciplinary approach. The epidemiology and risk factors associated with IH, including connections to prematurity, low birth weight, and family background, are discussed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!